Uniqure NV (QURE) Short Interest Down 36.7% in January

Uniqure NV (NASDAQ:QURE) was the recipient of a significant drop in short interest during the month of January. As of January 31st, there was short interest totalling 569,806 shares, a drop of 36.7% from the January 12th total of 900,303 shares. Based on an average daily trading volume, of 398,325 shares, the short-interest ratio is presently 1.4 days. Currently, 3.1% of the company’s shares are sold short.

QURE has been the topic of a number of research analyst reports. Zacks Investment Research raised Uniqure from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research report on Tuesday, February 6th. HC Wainwright set a $28.00 price target on Uniqure and gave the stock a “buy” rating in a research report on Thursday, December 7th. Leerink Swann raised their price target on Uniqure from $19.00 to $26.00 in a research report on Tuesday, November 7th. Oppenheimer reaffirmed a “hold” rating on shares of Uniqure in a research report on Friday, November 24th. Finally, ValuEngine raised Uniqure from a “sell” rating to a “hold” rating in a research report on Tuesday, December 26th. Three analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $19.88.

In other Uniqure news, insider Deventer Sander Van sold 5,985 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $18.53, for a total transaction of $110,902.05. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director David Schaffer sold 2,878 shares of the firm’s stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $18.53, for a total value of $53,329.34. Following the transaction, the director now owns 15,314 shares in the company, valued at approximately $283,768.42. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 41,510 shares of company stock worth $815,776. Company insiders own 0.73% of the company’s stock.

Institutional investors have recently made changes to their positions in the stock. SG Americas Securities LLC acquired a new stake in Uniqure in the 4th quarter valued at approximately $119,000. Virtus Fund Advisers LLC acquired a new stake in Uniqure in the 4th quarter valued at approximately $389,000. OxFORD Asset Management LLP acquired a new stake in Uniqure in the 3rd quarter valued at approximately $399,000. JPMorgan Chase & Co. raised its position in Uniqure by 33.5% in the 2nd quarter. JPMorgan Chase & Co. now owns 58,481 shares of the biotechnology company’s stock valued at $362,000 after buying an additional 14,659 shares during the last quarter. Finally, Victory Capital Management Inc. acquired a new stake in Uniqure in the 4th quarter valued at approximately $1,298,000. 24.97% of the stock is currently owned by institutional investors and hedge funds.

Shares of Uniqure (QURE) opened at $19.17 on Monday. Uniqure has a 1 year low of $4.72 and a 1 year high of $21.35. The stock has a market capitalization of $590.44, a P/E ratio of -7.34 and a beta of 0.57. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.64 and a quick ratio of 3.64.

COPYRIGHT VIOLATION NOTICE: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright & trademark law. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/12/uniqure-nv-qure-short-interest-down-36-7-in-january.html.

About Uniqure

Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply